Printer Friendly

DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION

 DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
 TORONTO, Ont., Jan. 9 /PRNewswire/ -- Deprenyl Research Limited


(TSE: DEP; NASDAQ: DEPLF) today announced that Canguard Health Technologies Inc., Neuromedica Inc. and Pharmascience Inc. have requested that Deprenyl Research Limited grant them more time to prepare materials to respond to Deprenyl Research Limited's application for an injunction restraining Canguard Health Technologies Inc., Neuromedica Inc. and Pharmascience Inc. from infringing its patent for Eldepryl(R).
 Canguard Health Technologies Inc. issued a statement on Jan. 8, 1992, indicating that it was launching a proceeding to be heard on Jan. 9, 1992, to dismiss Deprenyl Research Limited's action for patent infringement against Canguard Health Technologies Inc. and the others. On the same date, Canguard Health Technologies Inc. approached Deprenyl Research Limited to adjourn the proceeding to be heard on Jan. 9, 1992.
 Deprenyl Research Limited has consented to adjourn its application for an injunction on the following agreement by Canguard Health Technologies Inc., Neuromedica Inc. and Pharmascience Inc.:
 1. Canguard Health Technologies Inc.'s motion to strike out Deprenyl Research Limited's action for patent infringement has been adjourned.
 2. Canguard Health Technologies Inc., Neuromedica Inc. and Pharmascience Inc. will refrain from importing, selling, offering for sale, or using L-selegiline hydrochloride (the chemical name of Eldepryl) in Canada, using L-selegiline hydrochloride in any human trials in Canada, filing any documentation with the Government of Canada, including the Health Protection Branch, engaging in any new clinical testing of L-selegiline hydrochloride and engaging in any new lab testing of L-selegiline hydrochloride.
 Deprenyl Research Limited is an independent Canadian pharmaceutical company which markets drugs to treat central nervous system disorders. Its principal product is Elderpryl, which is used to treat Parkinson's disease.
 -0- 1/9/92
 /CONTACT: Morton P. Shulman, M.D., co-chairman, or James P. Doherty, president of Deprenyl, 416-537-4372; or Irving L. Straus of Straus Corporate Communications, 212-768-2477, for Deprenyl/
 (DEPLF) CO: Deprenyl Research Limited; Canguard Health Technologies Inc.;
 Neuromedica Inc.; Pharmascience Inc. ST: Ontario IN: MTC SU:


GK-KW -- NY069 -- 8357 01/09/92 15:53 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 9, 1992
Words:337
Previous Article:THE DAY THE MICE ROARED -- AND THE COURT LISTENED!
Next Article:CHEMICAL REPORTS 1991 EARNINGS OF $154 MILLION AFTER $625 MILLION MERGER-RELATED RESTRUCTURING CHARGE
Topics:


Related Articles
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO LAWSUIT ANNOUNCED IN PRESS ON DEC. 3
CANGUARD HEALTH TECHNOLOGIES ANNOUNCES LAWSUIT UPDATE
CANGUARD HEALTH TECHNOLOGIES ADJOURNMENT AGREEMENT
CANGUARD HEALTH TECHNOLOGIES RESPONSE TO DEPRENYL RELEASE
CANGUARD AND DEPRENYL RESEARCH LAWSUIT ADJOURNED TODAY; NO RESTRICTIONS IMPOSED ON CANGUARD
DEPRENYL RESEARCH COMMENTS ON STOCK PRICE
DEPRENYL RESEARCH CHAIRMAN ISSUES STATEMENT ON SELL ADVISORY
CANGUARD SERVES NOTICE OF MOTION, FINAL AFFIDAVITS ON DEPRENYL RESEARCH; ANNOUNCES NEW BUSINESS DEVELOPMENTS
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters